Eva Bandrés Elizalde-rekin lankidetzan egindako argitalpenak (11)

2013

  1. Valoración de marcadores pronósticos de respuesta a bevacizumab en pacientes con cáncer colorrectal avanzado y su utilidad para la individualización del tratamiento

    Anales del sistema sanitario de Navarra, Vol. 36, Núm. 1, pp. 174-177

2012

  1. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer

    European Journal of Cancer, Vol. 48, Núm. 12, pp. 1774-1780

  2. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array

    World Journal of Gastroenterology, Vol. 18, Núm. 7, pp. 637-645

  3. Identification of predictive circulating biomarkers of bevacizumab- containing regimen efficacy in pre-treated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 107, Núm. 2, pp. 287-290

2011

  1. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy

    European Journal of Cancer, Vol. 47, Núm. 6, pp. 839-847

  2. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells

    Stem Cells, Vol. 29, Núm. 11, pp. 1661-1671

2010

  1. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 103, Núm. 10, pp. 1529-1535

  2. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis

    British Journal of Cancer, Vol. 102, Núm. 6, pp. 987-994

  3. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation

    Molecular Cancer Therapeutics, Vol. 9, Núm. 8, pp. 2265-2275

2009

  1. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells

    Clinical Cancer Research, Vol. 15, Núm. 7, pp. 2281-2290

2007

  1. Combining chemotherapy and targeted therapies in metastatic colorectal cancer

    World Journal of Gastroenterology, Vol. 13, Núm. 44, pp. 5867-5876